Drug Trial Radar · NCT06311786
A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants
Last checked: Nov 19, 2026Latest source record: May 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Apr 8, 2024
Primary completion
May 11, 2024
Study completion May 11, 2024
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Mar 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main goal of this study is to learn how \[14C\]-BIIB091 moves through and is processed by the body and to look at how much of BIIB091's metabolites (what is produced when BIIB091 is broken down by the body) appears in the blood, urine, and stool in healthy male participants. The study will also help researchers learn more about the safety of BIIB091 in healthy male participants.
Conditions
- Healthy Volunteer
Interventions
[14C]-BIIB091Drug
Administered as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Amount of BIIB091 Excreted per Sampling Interval in Urine (Aeu)Time frame: Pre-dose and at multiple timepoints up to Day 10
- Amount of BIIB091 Excreted per Sampling Interval in Feces (Aef)Time frame: Pre-dose and at multiple timepoints up to Day 10
- Cumulative Amount of BIIB091 Excreted per Sampling Interval in Urine (Cum Aeu)Time frame: Pre-dose and at multiple timepoints up to Day 10
- Cumulative Amount of BIIB091 Excreted per Sampling Interval in Feces (Cum Aef)Time frame: Pre-dose and at multiple timepoints up to Day 10
- Percentage of BIIB091 Excreted per Sampling Interval in Urine (%Feu)Time frame: Pre-dose and at multiple timepoints up to Day 10
- Percentage of BIIB091 Excreted per Sampling Interval in Feces (%Fef)Time frame: Pre-dose and at multiple timepoints up to Day 10
- Cumulative Percentage of BIIB091 Excreted in Urine (Cum %Feu)Time frame: Pre-dose and at multiple timepoints up to Day 10
- Cumulative Percentage of BIIB091 Excreted in Feces (Cum %Fef)Time frame: Pre-dose and at multiple timepoints up to Day 10
- Maximum Observed Concentration (Cmax) of [14C]-BIIB091-Derived Materials in Plasma and Whole BloodTime frame: Pre-dose and at multiple timepoints up to Day 5
- Time to Reach Maximum Observed Concentration (Tmax) of [14C]-BIIB091-Derived Materials in Plasma and Whole BloodTime frame: Pre-dose and at multiple timepoints up to Day 5
- Area Under the Concentration-Time Curve From Time 0 to Time of the Last Measurable Concentration (AUClast) of [14C]-BIIB091-Derived Materials in Plasma and Whole BloodTime frame: Pre-dose and at multiple timepoints up to Day 5
- Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of [14C]-BIIB091-Derived Materials in Plasma and Whole BloodTime frame: Pre-dose and at multiple timepoints up to Day 5
- Terminal Half-Life (t1/2) of [14C]-BIIB091-Derived Materials in Plasma and Whole BloodTime frame: Pre-dose and at multiple timepoints up to Day 5
- Apparent Clearance (CL/F) of BIIB091 in PlasmaTime frame: Pre-dose and at multiple timepoints up to Day 5
- Apparent Volume of Distribution (Vz/F) of BIIB091 in PlasmaTime frame: Pre-dose and at multiple timepoints up to Day 5
- Quantitative Profile of [14C]-BIIB091 Metabolites in PlasmaTime frame: Pre-dose and at multiple timepoints up to Day 4
- Quantitative Profile of [14C]-BIIB091 Metabolites in UrineTime frame: Pre-dose and at multiple timepoints up to Day 10
- Quantitative Profile of [14C]-BIIB091 Metabolites in FecesTime frame: Pre-dose and at multiple timepoints up to Day 10
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PPD Clinical Research Unit
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.